Sona Nanotech Inc. is pleased to announce that it has received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory. In addition to running similar assessments to those that have been previously announced for contamination and endotoxin levels, this assessment included an analysis of the surfactant residue present following the chemical reaction necessary for the manufacture of Sona’s proprietary gold nanorods.

This is sponsored content issued on behalf of Sona Nanotech, please see full disclaimer here.


More From The Market Online

Four of the Magnificent Seven dropped today: Here’s why

The Magnificent Seven generated nearly two-thirds of the S&P 500's returns in 2023 and account for more than 25 per cent of the index.

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Buzz on the Bullboards: A recap of recent activity and stocks in focus

After a major sell-off, stock markets have been on edge, monitoring corporate earnings to gauge the direction of the economy.